Abstract
Background The association between cancer survivors and heart disease mortality remains unclear. This study analyzed the risk of fatal heart disease in cancer survivors.
Methods Data from the Osaka Cancer Registry collected between 1985 and 2013 and data from the vital statistics in Japan were retrospectively analyzed. Causes of death were investigated.
Standardized mortality ratios (SMRs) were calculated to compare the risk of fatal heart disease between patients with cancer and the general population. Poisson regression models were used to estimate the risk of fatal heart disease in patients with cancer and other cancer subgroups.
Results In total, 688,473 cancer patients were included in the analysis, and 337,117 patients died during the study period. Among them, 10,781 patients died of heart disease, with 5,020 of these patients having ischemic heart disease; 3,602 patients, heart failure; 441 patients, hypertensive disease; and 1,718 patients, other heart diseases. The SMR (95% confidence interval [CI]) for heart disease was 2.85 (2.80–2.91). The SMRs (95% CIs) for ischemic heart disease, heart failure, and hypertensive disease were 3.26 (3.17–3.35); 2.69 (2.60–2.78), and 4.47 (4.07–4.90), respectively. The risk of fatal heart disease increased over time after cancer diagnosis. The multivariable Poisson regression model showed that males were more likely to die of heart disease than females (relative risk, 1.39; 95% CI, 1.34–1.45). Notably, the risk of fatal heart disease among cancer survivors has decreased in recent years.
Conclusions Cancer survivors have a higher risk of fatal heart disease than the general population.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
This work was supported by the Ministry of Health, Labor, and Welfare Sciences Research Grant [grant number:20EA1026].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent was waived owing to the retrospective nature of the study. The Institutional Review Board of Osaka University, Suita, Japan, approved the study protocol (approval number: 17315-3).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
Data are available on reasonable request to the corresponding author.
Abbreviations
- CIs
- confidence intervals
- ICD
- International Classification of Diseases
- NANDE
- Neoplasms ANd other causes of DEath
- OCR
- Osaka Cancer Registry
- RR
- relative risk
- SEER
- Surveillance, Epidemiology, and End Results
- SMRs
- standardized mortality ratios
